SG11201601642WA - Compositions for the treatment of hypertension and/or fibrosis - Google Patents

Compositions for the treatment of hypertension and/or fibrosis

Info

Publication number
SG11201601642WA
SG11201601642WA SG11201601642WA SG11201601642WA SG11201601642WA SG 11201601642W A SG11201601642W A SG 11201601642WA SG 11201601642W A SG11201601642W A SG 11201601642WA SG 11201601642W A SG11201601642W A SG 11201601642WA SG 11201601642W A SG11201601642W A SG 11201601642WA
Authority
SG
Singapore
Prior art keywords
fibrosis
hypertension
compositions
treatment
Prior art date
Application number
SG11201601642WA
Other languages
English (en)
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903573A external-priority patent/AU2013903573A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of SG11201601642WA publication Critical patent/SG11201601642WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201601642WA 2013-09-17 2014-09-17 Compositions for the treatment of hypertension and/or fibrosis SG11201601642WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013903573A AU2013903573A0 (en) 2013-09-17 Compositions for the treatment of hypertension and/or fibrosis
PCT/AU2014/000923 WO2015039173A1 (en) 2013-09-17 2014-09-17 Compositions for the treatment of hypertension and/or fibrosis

Publications (1)

Publication Number Publication Date
SG11201601642WA true SG11201601642WA (en) 2016-04-28

Family

ID=52687998

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601642WA SG11201601642WA (en) 2013-09-17 2014-09-17 Compositions for the treatment of hypertension and/or fibrosis

Country Status (22)

Country Link
US (1) US9458093B2 (uk)
EP (1) EP3046901B1 (uk)
JP (1) JP6122548B2 (uk)
KR (1) KR101736416B1 (uk)
CN (1) CN105683152B (uk)
AP (1) AP2016009079A0 (uk)
AU (1) AU2014324078B2 (uk)
BR (1) BR112016005601B1 (uk)
CA (1) CA2924356C (uk)
DK (1) DK3046901T3 (uk)
ES (1) ES2655455T3 (uk)
IL (1) IL244621A (uk)
MX (1) MX368865B (uk)
MY (1) MY172557A (uk)
NO (1) NO3046901T3 (uk)
NZ (1) NZ717927A (uk)
PH (1) PH12016500497B1 (uk)
PL (1) PL3046901T3 (uk)
RU (1) RU2635564C2 (uk)
SG (1) SG11201601642WA (uk)
UA (1) UA118111C2 (uk)
WO (1) WO2015039173A1 (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
KR102591689B1 (ko) * 2015-03-18 2023-10-18 벡투스 바이오시스템즈 리미티드 섬유증 및 섬유증 관련 질병 치료용 조성물
CA2979407C (en) * 2015-03-18 2023-05-23 Vectus Biosystems Limited Compositions for the treatment of kidney and/or liver disease
DK3353147T3 (da) 2015-09-22 2021-03-29 Vectus Biosystems Ltd Syntese af terphenylforbindelser
IL298314A (en) * 2016-04-13 2023-01-01 Univ Nebraska Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin
DK3490970T3 (da) * 2016-07-28 2024-01-02 Vectus Biosystems Ltd Sammensætninger til behandling af lungefibrose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694288B1 (fr) * 1992-06-30 1994-09-09 Rhone Poulenc Agrochimie Phenylbenzamides fongicides et procédés pour les préparer.
KR101638308B1 (ko) * 2004-06-11 2016-07-08 벡투스 바이오시스템즈 리미티드 심혈관 질환의 치료를 위한 조성물 및 방법
KR20140041943A (ko) * 2005-12-09 2014-04-04 벡투스 바이오시스템즈 피티와이 리미티드 Vip 단편 및 사용 방법
US20120088737A2 (en) 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
US9630935B2 (en) * 2013-09-17 2017-04-25 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis

Also Published As

Publication number Publication date
RU2635564C2 (ru) 2017-11-14
NZ717927A (en) 2018-12-21
AU2014324078B2 (en) 2016-12-15
CA2924356C (en) 2018-04-03
ES2655455T3 (es) 2018-02-20
MX368865B (es) 2019-08-02
IL244621A (en) 2017-04-30
UA118111C2 (uk) 2018-11-26
WO2015039173A1 (en) 2015-03-26
BR112016005601A8 (pt) 2020-02-18
JP6122548B2 (ja) 2017-04-26
DK3046901T3 (en) 2018-01-02
MY172557A (en) 2019-12-02
KR101736416B1 (ko) 2017-05-16
RU2016112257A (ru) 2017-10-20
KR20160074471A (ko) 2016-06-28
BR112016005601B1 (pt) 2021-02-02
CN105683152B (zh) 2017-03-22
CN105683152A (zh) 2016-06-15
EP3046901A1 (en) 2016-07-27
US20160221933A1 (en) 2016-08-04
PL3046901T3 (pl) 2018-03-30
PH12016500497A1 (en) 2016-06-13
EP3046901A4 (en) 2017-04-12
AP2016009079A0 (en) 2016-03-31
AU2014324078A1 (en) 2016-04-07
IL244621A0 (en) 2016-04-21
CA2924356A1 (en) 2015-03-26
MX2016003371A (es) 2016-10-21
EP3046901B1 (en) 2017-10-18
US9458093B2 (en) 2016-10-04
JP2016532632A (ja) 2016-10-20
NO3046901T3 (uk) 2018-03-17
PH12016500497B1 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
IL265876A (en) Preparations that include 15-ohepa and methods of using them
HK1214171A1 (zh) 賽尼克韋羅組合物及其製備和使用方法
HK1224210A1 (zh) 用於治療纖維化的方法和組合物
IL244621A (en) Preparations for the treatment of hypertension and / or fibrosis
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
SG11201601921RA (en) Azeotrope-like compositions of fo-e-1,3,4,4,4-pentafluoro-3-trifluoromethyl-1-butene and e-1-chloro-3,3,3-trifluoropropene and uses thereof
ZA201706985B (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
AU2013903571A0 (en) Compositions for the treatment of hypertension and/or fibrosis
AU2013903572A0 (en) Compositions for the treatment of hypertension and/or fibrosis
AU2013903573A0 (en) Compositions for the treatment of hypertension and/or fibrosis
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
AU2013901658A0 (en) Compositions and methods for the treatment of tinnitus
AU2013901209A0 (en) Compositions and methods for the treatment of cystic fibrosis